Journal of Hematology and Oncology Research

Submit Manuscript

Journal of Hematology and Oncology Research · ISSN 2372-6601

Editorial Board

The editors who assess submissions to this journal, with affiliations, countries, research interests, and available ORCID iDs provided for transparency.

  • 63 Editors, including the Editor-in-Chief
  • 23 Countries represented
  • 49 Members with a public ORCID iD
  • 63 Affiliations on record

Membership and affiliations are loaded from the journal’s public database records.

Krzysztof Roszkowski, Professor, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz

Editor-in-Chief

Krzysztof Roszkowski

Professor, Nicolaus Copernicus University Collegium Medicum, Bydgoszcz

Poland

Potential clinical use of biomarkers of oxidative DNA damage and systems of reparation. DNA damage and repair mechanisms through neoplastic and health

Board members

Listed alphabetically by family name. Every entry gives the institution on record and links to the member’s full profile.

  • Agnieszka Żyromska, Oncology Center, Bydgoszcz

    Agnieszka Żyromska

    Oncology Center, Bydgoszcz

    Poland

    Radiation biology; Paediatrics cancers; Hypoxia; Cancer cell biology; Cancer Biomarkers;

  • Almuradova Dilbar Muradovna, Assistant of the Department of Oncology and Ray diagnosis TMA

    Almuradova Dilbar Muradovna

    Assistant of the Department of Oncology and Ray diagnosis TMA

    Uzbekistan

    Modern approaches to the diagnosis and treatment of triple negative breast cancer, General oncology, Medical oncology, Oncology and Radiology

  • Arun Srivastav, Cancer and Genetics Research Complex, University of Florida College of Medicine, 2033 Mowry Road, Room 492-A, Gainesville, FL 32611-3633, USA

    Arun Srivastav

    Cancer and Genetics Research Complex, University of Florida College of Medicine, 2033 Mowry Road, Room 492-A, Gainesville, FL 32611-3633, USA

    United States

    Adeno-Associated Viral Gene Therapy, Hematology, Liver Disease.

  • Bahram Alamdary Badlou, Head, BBAdvies and Research, Zeist, Utrecht

    Bahram Alamdary Badlou

    Head, BBAdvies and Research, Zeist, Utrecht

    Netherlands

    Cardiovascular disease, Platelets, Cold, Metabolism, Energy, PRP, Transfusion, Transplantation, Calcium, ATP, Biology, Blood, Celltherapy

  • Benedetto Sacchetti, University of Turin, Italy

    Benedetto Sacchetti

    University of Turin, Italy

    Italy

  • Cees Smit Sibinga, Professor of International Development of Transfusion Medicine (IDTM), University of Groningen, Groningen, NL

    Cees Smit Sibinga

    Professor of International Development of Transfusion Medicine (IDTM), University of Groningen, Groningen, NL

    Netherlands

    Internal Medicine, Clinical Haematology, Transfusion Medicine including Quality/Risk Management and Executive Management, immunohaematology, infectious disease marker screening

  • Emmanuel Andres, Professor, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace

    Emmanuel Andres

    Professor, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace

    France

    cytopenia - anemia - thrombocytopenia - neutropenia - agranulocytosis - cationic antimicrobial peptide - innate immunity - telemedecine - stethoscope -pedagogy

  • Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, Senior Lecturer

    Emmanuel Ifeanyi Obeagu

    Department of Medical Laboratory Science, Kampala International University, Uganda, Senior Lecturer

    Uganda

    Autoimmunity, Immunology of Infectious Diseases, Inflammation, HIV, Flow Cytometry, Infection, Journalism, Immunity, Antioxidants, Public Health

  • Erxi Wu, Department of Neurosurgery, Baylor Scott & White Health, Temple, TX

    Erxi Wu

    Department of Neurosurgery, Baylor Scott & White Health, Temple, TX

    United States

    Tumor therapeutic targets, drug targets, biomarkers, drug discovery

  • Goot Heah Khor, Senoir Lecturer, Universiti Teknologi MARA, Sungai Buluh Campus, Sungai Buluh , Selangor

    Goot Heah Khor

    Senoir Lecturer, Universiti Teknologi MARA, Sungai Buluh Campus, Sungai Buluh , Selangor

    Malaysia

    Cancer biology, molecular biology, oral oncology, histochemistry

  • Guru Prasad Maiti, Assistant Staff Scientist, Oklahoma Medical Research Foundation, Oklahoma City, OK

    Guru Prasad Maiti

    Assistant Staff Scientist, Oklahoma Medical Research Foundation, Oklahoma City, OK

    United States

    Cancer Biology, RNA, Cell Culture, Gene Expression, DNA, Western Blot Analysis, Immunohistochemistry, Immunofluorescence, Electrophoresis

  • Hassan Rafieemehr, Hamadan university of medical sciences, Hamadan

    Hassan Rafieemehr

    Hamadan university of medical sciences, Hamadan

    Iran

    Regenerative Medicine, Cell Culture, Stem Cell Biology, Stem Cell Differentiation, Differentiation, Flow Cytometry, Immunohistochemistry, PCR, Immunofluorescence, Cell Proliferation

  • Iffat Jamal, Indira Gandhi Institute of Medical Sciences, India

    Iffat Jamal

    Indira Gandhi Institute of Medical Sciences, India

    India

    Immunopathology, Molecular and cytogenetics, Clinical pathology, Coagulation, Cytopathology, Hematopathology, Histopathology, Genetics, Research, Surgical

  • Jayadev Manikkam Umakanthan

    University of North Carolina Physician Network, United States

    United States

    Breast Cancer Lung Cancer Leukemia, Lymphoma and Myeloma

  • Jonas Cicenas, Assistant Professor, Kauno Kolegija, Kaunas

    Jonas Cicenas

    Assistant Professor, Kauno Kolegija, Kaunas

    Lithuania

    kinases, cancer, GDPases, bioinformatics, biostatistics, biocuration

  • Mazdak Ganjalikhani-Hakemi, Associate professor/Sinior researched, Istanbul Medipol University, Istanbul

    Mazdak Ganjalikhani-Hakemi

    Associate professor/Sinior researched, Istanbul Medipol University, Istanbul

    Turkey

    Cancer Immunotherapy RNAi Immunology

  • Michael Jaglal, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

    Michael Jaglal

    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL

    United States

    Hematology, Oncology, Brain Cancer, Leukemia

  • Muhamad Ramadan Abdel-Hameed Abdel-Nabi, Faculty of Medicine, Assiut University, Egypt.

    Muhamad Ramadan Abdel-Hameed Abdel-Nabi

    Faculty of Medicine, Assiut University, Egypt.

    Egypt

    Clinical Hematology, BM Transplantation

  • Natalia Malara, Associate professor, Magna Graecia University, Catanzaro, Calabria

    Natalia Malara

    Associate professor, Magna Graecia University, Catanzaro, Calabria

    Italy

    circulating tumor cells, circulating endothelial cells, personalized oncologic therapy, early cancer detection

  • Prasad S Koka, Biomedical Research Institute of Southern California, United States

    Prasad S Koka

    Biomedical Research Institute of Southern California, United States

    United States

    Hematologic Diseases, Hematopoietic Stem Cell Transplantation, microRNA, Flow Cytometry, Stem Cell Biology, PCR, Western Blot Analysis, Cloning, Blood Disorders, Immunohistochemistry

  • Rada M. Grubovic, Scientific Program Manager, Conseil de L'Europe, Strasbourg

    Rada M. Grubovic

    Scientific Program Manager, Conseil de L'Europe, Strasbourg

    France

    Stem cell collection

  • Rafael Coveñas, University of Salamanca, Spain

    Rafael Coveñas

    University of Salamanca, Spain

    Spain

    Neuropeptides, diencephalon, immunocytochemistry, multiple sclerosis, NK-1 receptor, cancer

  • Saoussen Chouchene

    University of Monastir

    Tunisia

    Hematology Hemostasis Immunohematology

  • Shuaiying Cui, Boston University School of Medicine, United States

    Shuaiying Cui

    Boston University School of Medicine, United States

    United States

    Hematologic Disorders, Sickle Cell Disease, Beta-thalassemia, Acute Myeloid Leukemia, Blood cancer

  • Sunatee Sa-nguansai

    Mahidol University

    Thailand

    Medical Oncology

  • Vincenzo Canzonieri, Associate Professor of Pathology , Università degli Studi di Trieste, Trieste, Friuli-Venezia Giulia

    Vincenzo Canzonieri

    Associate Professor of Pathology , Università degli Studi di Trieste, Trieste, Friuli-Venezia Giulia

    Italy

    Pathological Anatomy, Forensic Medicine, General Oncology

  • Wafik S. El-Deiry, Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, RI

    Wafik S. El-Deiry

    Associate Dean, Oncologic Sciences, Warren Alpert Medical School, Brown University, Providence, RI

    United States

    Molecular Oncology, Cancer Molecular Targets and Therapeutics Section, Pharmacology and Genetics, Hematology, Oncology

  • Wala Ben Kridis, Associate professor, Hopital Universitaire Habib Bourguiba, Sfax

    Wala Ben Kridis

    Associate professor, Hopital Universitaire Habib Bourguiba, Sfax

    Tunisia

    Oncology,Chemotherapy, Targeted therapy

  • Yi Shan

    University of Massachusetts Medical School.

    United States

    CML, AML, BALL, MPD, Leukemia stem cell, Cancer biology, Cancer gene therapy.

  • Zheng Xu, Associate Research Scientist, Columbia University in the City of New York.

    Zheng Xu

    Associate Research Scientist, Columbia University in the City of New York.

    United States

    The negative regulatory functions of ILT3 in T cell activation and cancer cell proliferation. The molecular link between miRNA, inflammation and Carcinogenesis. The role of miRNA in the innate immunity (especially in the Toll like receptor and type I IFN signaling pathway) and the interplay between host, pathogen and miRNAs The role of miRNA in the ILT3 induced inhibitory effects in immune system.

  • Zilu Zhu, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA

    Zilu Zhu

    Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA

    United States

    B cell, signal transduction, autoimmune disease, inflammation, Fc receptor, FCRL

  • Vladimir Pak, Research Scientist Omega Alpha Pharmaceuticals United States

    Vladimir Pak

    Research Scientist Omega Alpha Pharmaceuticals United States

    Molecular Biology, specifically Apobec3, HIV, transcription.

  • Andreas Petzer, Head Internal Medicine I: Medical Oncology, Hematology and Gastroenterology Barmherzige Schwestern Hospital Linz,

    Andreas Petzer

    Head Internal Medicine I: Medical Oncology, Hematology and Gastroenterology Barmherzige Schwestern Hospital Linz,

    AUSTRIA

    Chronic myelogenous Leukemia (CML) Stem cell biology

  • Fernando Luiz Affonso Fonseca, Institute of Chemical Sciences Federal University of São Paulo, UNIFESP Head of Laboratory of Clinical Analysis of the Faculty of Medicine of ABC, Santo André, SP, Brazil.

    Fernando Luiz Affonso Fonseca

    Institute of Chemical Sciences Federal University of São Paulo, UNIFESP Head of Laboratory of Clinical Analysis of the Faculty of Medicine of ABC, Santo André, SP, Brazil.

    Brazil

    Oncology

  • Anup Kasi Loknath Kumar, University of Kansas Medical Center, United States

    Anup Kasi Loknath Kumar

    University of Kansas Medical Center, United States

    United States

    Oncology Hematology GI oncology

  • Bachir Benarba, Director, Thematic Research Agency in Health and Life Sciences, Oran

    Bachir Benarba

    Director, Thematic Research Agency in Health and Life Sciences, Oran

    Algeria

    Cancer; Natural products; Apoptosis; Ethnobotany; Nutrition; Phytochemistry; Biochemistry

  • Bashir A. Lwaleed, University of Southampton, Southampton, England

    Bashir A. Lwaleed

    University of Southampton, Southampton, England

    United Kingdom

    Cancer Biology, Flow Cytometry, Immunology, Cancer Research, Cancer Cells, Histology, Cancer Immunology, Hematology, Chemotherapy, Coagulation, Thrombosis, Blood Coagulation, Haemostasis, Cell Therapy.

  • Cesar A. Perez, University of Louisville, Louisville, KY

    Cesar A. Perez

    University of Louisville, Louisville, KY

    united states

    Targeted therapies, Malignant Hematology, Lymphomas, Multiple Myeloma, Head and Neck Cancer, Lung Cancer, Refractory Thyroid Cancer, Multi-kinase inhibitors.

  • Dumrul Gulen, Department of Microbiology

    Dumrul Gulen

    Department of Microbiology

    Turkey

    Tumor Biology, Tumor Immunology, Dendritic cell Vaccines, Stem Cells, Human Dendritic Cells,

  • Guo-Qiang Chen, Shanghai Jiao Tong University, Shanghai

    Guo-Qiang Chen

    Shanghai Jiao Tong University, Shanghai

    China

    Leukemia, hepatocellular carcinoma, chemical biology, signaling pathway, cell differentiation and death

  • Hehuang Xie, Professor, Virginia Polytechnic Institute and State University, Blacksburg, VA

    Hehuang Xie

    Professor, Virginia Polytechnic Institute and State University, Blacksburg, VA

    United States

    DNA methylation

  • Hesham Mourad, Pharmacy Informatics Team Leader, Mayo Clinic Florida, Jacksonville, FL

    Hesham Mourad

    Pharmacy Informatics Team Leader, Mayo Clinic Florida, Jacksonville, FL

    United States

    Hematology, oncology

  • Houjie Liang, Department of Oncology,Southwest Hospital

    Houjie Liang

    Department of Oncology,Southwest Hospital

    China

    The mechanism, diagnosis and treatment of tumor

  • Hui Ling, MD Anderson Cancer Center

    Hui Ling

    MD Anderson Cancer Center

    United States

    microRNA and non-coding RNA, cancer research, epigenetics, genomic instability, natural products originated anticancer compounds

  • John Allan, Weill Cornell Medical College, NY, NY

    John Allan

    Weill Cornell Medical College, NY, NY

    United States

    Plasma Cell Dyscrasias Leukemia Stem Cell Biology Coagulation

  • John Park

    National Research Center Institute of Immunology FMBA Moscow Russia

  • Jose Pablo Leone, Dana-Farber Cancer Institute

    Jose Pablo Leone

    Dana-Farber Cancer Institute

    United States

    brain metastases, male breast cancer and novel therapies in the treatment of breast cancer.

  • Ksenia Matlawska-Wasowska, Associate Professor, University of Alabama at Birmingham, Birmingham, Alabama

    Ksenia Matlawska-Wasowska

    Associate Professor, University of Alabama at Birmingham, Birmingham, Alabama

    United States

    leukemia, immunobiology, cell biology

  • Marco Gambarotti, IRCCS - Istituto Ortopedico Rizzoli, Bologna, BO

    Marco Gambarotti

    IRCCS - Istituto Ortopedico Rizzoli, Bologna, BO

    Italy

    Bone & soft tissue tumors, bone & soft tissue diseases, joint diseases

  • Nikolaos Panagiotopoulos, University College London Hospitals UCLH

    Nikolaos Panagiotopoulos

    University College London Hospitals UCLH

    United Kingdom

    Epidemiology of lung cancer Robotic Thoracic Surgery Inflammatory response in minimally invasive Thoracic Surgery

  • Seong-Su Han

    Assistant Professor, UNMC, Omaha, Nebraska

    United States

    Signal transduction / Chemoprevention reesrach with blood cancer, especially leukemia and lymphoma. Most of my work has focused on molecular and cellular ocology research to elucidate the signal transduction pathways involved in the tumorigenesis mechanisms and to validate the action of various kinds of natural phytochemicals or synthetic chemicals using gene-targeted mouse model for novel target discovery and validation leading to therapeutic application.

  • Shulin Li, The University of Texas MD Anderson Cancer Center, Houston, Texas

    Shulin Li

    The University of Texas MD Anderson Cancer Center, Houston, Texas

    United States

    immune therapy, gene therapy, circulating tumor cells

  • Simon Abi Aad

    Icahn School of Medicine at Mount Sinai St. Lukes-Roosevelt Hospital Center

    United States

    Hematology-Oncology, Survivorship; Side-effects

  • Umit Tapan, Assistant Professor, Boston University School of Medicine, Boston, MA

    Umit Tapan

    Assistant Professor, Boston University School of Medicine, Boston, MA

    United States

    Cancer biomarker research.

  • Venu Thirukonda, Billings Clinic Cancer center

    Venu Thirukonda

    Billings Clinic Cancer center

    United States

    Hematologic malignancies Lung cancer

  • XIN QING, Head, Hematopathology Director, Hematology and Flow Cytometry Laboratory

    XIN QING

    Head, Hematopathology Director, Hematology and Flow Cytometry Laboratory

    United States

  • Xingding Zhang, Professor/Assistant Dean, Sun Yat-Sen University, Shenzhen, Guangdong

    Xingding Zhang

    Professor/Assistant Dean, Sun Yat-Sen University, Shenzhen, Guangdong

    China

    Lymphoma/ Myeloma

  • Xinyang Zhao, associate professor, The University of Kansas Medical Center, Kansas City, KS

    Xinyang Zhao

    associate professor, The University of Kansas Medical Center, Kansas City, KS

    United States

    arginine methylation

  • Hadi Yaziji, Vitro Molecular Laboratories

    Hadi Yaziji

    Vitro Molecular Laboratories

    United States

    Cancer translational research

  • Radu Bucur Gologan, Fundeni Clinical Institute, Hematological Department

    Radu Bucur Gologan

    Fundeni Clinical Institute, Hematological Department

    Romania

    Myelodysplastic syndrome Acute and chronic leukemias Hereditary and acquired anemias Autoimmune hematological disorders Hodgkin and nonHodgkin lymphoma

  • Salvatore Papa, Associate Professor, University of Leeds, Leeds, Leeds

    Salvatore Papa

    Associate Professor, University of Leeds, Leeds, Leeds

    United Kingdom

    Inflammation , Cancer, Cell signalling, Metabolism

  • Selcuk DEMIRAL, Gülhane Training and Research Hospital

    Selcuk DEMIRAL

    Gülhane Training and Research Hospital

    Turkey

    Radiation Dosimetry Radiation Oncology Radiotherapy Brachytherapy Radiosurgery

Research-interest terms on board records

These figures summarize research-interest terms stored for the public board members each time the page loads. They do not independently verify expertise.

  • Potential clinical use of biomarkers of oxidative DNA damage and systems of reparation. DNA damage and repair mechanisms through neoplastic and health1
  • Radiation biology1
  • Paediatrics cancers1
  • Hypoxia1
  • Cancer cell biology1
  • Cancer Biomarkers1
  • Modern approaches to the diagnosis and treatment of triple negative breast cancer1
  • General oncology1
  • Medical oncology1
  • Oncology and Radiology1
  • Adeno-Associated Viral Gene Therapy1
  • Hematology5
  • Liver Disease.1
  • Cardiovascular disease1
  • Platelets1
  • Cold1
  • Metabolism2
  • Energy1
  • PRP1
  • Transfusion1
  • Transplantation1
  • Calcium1
  • ATP1
  • Biology1
  • Blood1
  • Celltherapy1
  • Internal Medicine1
  • Clinical Haematology1
  • Transfusion Medicine including Quality/Risk Management and Executive Management1
  • immunohaematology1
  • infectious disease marker screening1
  • cytopenia - anemia - thrombocytopenia - neutropenia - agranulocytosis - cationic antimicrobial peptide - innate immunity - telemedecine - stethoscope -pedagogy1
  • Autoimmunity1
  • Immunology of Infectious Diseases1
  • Inflammation2
  • HIV2
  • Flow Cytometry4
  • Infection1
  • Journalism1
  • Immunity1
  • Antioxidants1
  • Public Health1
  • Tumor therapeutic targets1
  • drug targets1
  • biomarkers1
  • drug discovery1
  • Cancer biology2
  • molecular biology1
  • oral oncology1
  • histochemistry1
  • Cancer Biology2
  • RNA1
  • Cell Culture2
  • Gene Expression1
  • DNA1
  • Western Blot Analysis2
  • Immunohistochemistry3
  • Immunofluorescence2
  • Electrophoresis1
  • Regenerative Medicine1
  • Stem Cell Biology2
  • Stem Cell Differentiation1
  • Differentiation1
  • PCR2
  • Cell Proliferation1
  • Immunopathology1
  • Molecular and cytogenetics1
  • Clinical pathology1
  • Coagulation2
  • Cytopathology1
  • Hematopathology1
  • Histopathology1
  • Genetics1
  • Research1
  • Surgical1
  • Breast Cancer Lung Cancer Leukemia1
  • Lymphoma and Myeloma1
  • kinases1
  • cancer2
  • GDPases1
  • bioinformatics1
  • biostatistics1
  • biocuration1
  • Cancer Immunotherapy RNAi Immunology1
  • Oncology4
  • Brain Cancer1
  • Leukemia2
  • Clinical Hematology1
  • BM Transplantation1
  • circulating tumor cells2
  • circulating endothelial cells1
  • personalized oncologic therapy1
  • early cancer detection1
  • Hematologic Diseases1
  • Hematopoietic Stem Cell Transplantation1
  • microRNA1
  • Cloning1
  • Blood Disorders1
  • Stem cell collection1
  • Neuropeptides1
  • diencephalon1
  • immunocytochemistry1
  • multiple sclerosis1
  • NK-1 receptor1
  • Hematology Hemostasis Immunohematology1
  • Hematologic Disorders1
  • Sickle Cell Disease1
  • Beta-thalassemia1
  • Acute Myeloid Leukemia1
  • Blood cancer1
  • Medical Oncology1
  • Pathological Anatomy1
  • Forensic Medicine1
  • General Oncology1
  • Molecular Oncology1
  • Cancer Molecular Targets and Therapeutics Section1
  • Pharmacology and Genetics1
  • Chemotherapy2
  • Targeted therapy1
  • CML1
  • AML1
  • BALL1
  • MPD1
  • Leukemia stem cell1
  • Cancer gene therapy.1
  • The negative regulatory functions of ILT3 in T cell activation and cancer cell proliferation. The molecular link between miRNA1
  • inflammation and Carcinogenesis. The role of miRNA in the innate immunity (especially in the Toll like receptor and type I IFN signaling pathway) and the interplay between host1
  • pathogen and miRNAs The role of miRNA in the ILT3 induced inhibitory effects in immune system.1
  • B cell1
  • signal transduction1
  • autoimmune disease1
  • inflammation1
  • Fc receptor1
  • FCRL1
  • Molecular Biology1
  • specifically Apobec31
  • transcription.1
  • Chronic myelogenous Leukemia (CML) Stem cell biology1
  • Oncology Hematology GI oncology1
  • Cancer2
  • Natural products1
  • Apoptosis1
  • Ethnobotany1
  • Nutrition1
  • Phytochemistry1
  • Biochemistry1
  • Immunology1
  • Cancer Research1
  • Cancer Cells1
  • Histology1
  • Cancer Immunology1
  • Thrombosis1
  • Blood Coagulation1
  • Haemostasis1
  • Cell Therapy.1
  • Targeted therapies1
  • Malignant Hematology1
  • Lymphomas1
  • Multiple Myeloma1
  • Head and Neck Cancer1
  • Lung Cancer1
  • Refractory Thyroid Cancer1
  • Multi-kinase inhibitors.1
  • Tumor Biology1
  • Tumor Immunology1
  • Dendritic cell Vaccines1
  • Stem Cells1
  • Human Dendritic Cells1
  • hepatocellular carcinoma1
  • chemical biology1
  • signaling pathway1
  • cell differentiation and death1
  • DNA methylation1
  • oncology1
  • The mechanism1
  • diagnosis and treatment of tumor1
  • microRNA and non-coding RNA1
  • cancer research1
  • epigenetics1
  • genomic instability1
  • natural products originated anticancer compounds1
  • Plasma Cell Dyscrasias Leukemia Stem Cell Biology Coagulation1
  • brain metastases1
  • male breast cancer and novel therapies in the treatment of breast cancer.1
  • leukemia1
  • immunobiology1
  • cell biology1
  • Bone & soft tissue tumors1
  • bone & soft tissue diseases1
  • joint diseases1
  • Epidemiology of lung cancer Robotic Thoracic Surgery Inflammatory response in minimally invasive Thoracic Surgery1
  • Signal transduction / Chemoprevention reesrach with blood cancer1
  • especially leukemia and lymphoma. Most of my work has focused on molecular and cellular ocology research to elucidate the signal transduction pathways involved in the tumorigenesis mechanisms and to validate the action of various kinds of natural phytochemicals or synthetic chemicals using gene-targeted mouse model for novel target discovery and validation leading to therapeutic application.1
  • immune therapy1
  • gene therapy1
  • Hematology-Oncology1
  • Survivorship1
  • Side-effects1
  • Cancer biomarker research.1
  • Hematologic malignancies Lung cancer1
  • Lymphoma/ Myeloma1
  • arginine methylation1
  • Cancer translational research1
  • Myelodysplastic syndrome Acute and chronic leukemias Hereditary and acquired anemias Autoimmune hematological disorders Hodgkin and nonHodgkin lymphoma1
  • Cell signalling1
  • Radiation Dosimetry Radiation Oncology Radiotherapy Brachytherapy Radiosurgery1

Members are counted in every area their recorded interests match, so these figures can sum to more than the size of the board. Authors should use the aims and scope to assess journal fit.

What the board is responsible for

Each statement below is taken from the journal's own published policy, and names the page it comes from.

  • What an editor decides

    Editors are described by the journal as scientific stewards responsible for rigor, integrity, and patient relevance, applying consistent standards across study designs, clinical settings, and geographic contexts.

    Initial screening covers scope alignment, the quality of the title and abstract, and whether the work adds knowledge beyond an incremental or redundant analysis. A manuscript is rejected when it is out of scope, methodologically flawed, or lacks clinical relevance.

    Source: Editor Guidelines
  • How review is organized

    Manuscripts that proceed to external peer review are normally evaluated by at least two independent subject-matter experts.

    Revisions are assessed by comparing the authors' responses against the reviewers' comments. Appeals are handled with a documented rationale and, where needed, further independent review.

    Source: Editorial Policies
  • Ethics and competing interests

    Editors require conflict-of-interest disclosure, funding statements and author contribution details, and screen for plagiarism, duplicate publication and image manipulation.

    JHOR follows COPE guidance on suspected misconduct: editors document the evidence, consult editorial leadership, and follow the established investigation protocol. Corrections, expressions of concern and retractions are issued under the same guidance.

    Source: Editorial Policies · Editor Guidelines

How a manuscript is reviewed

Review model
Single-blind (double-blind on request)
External peer review
Normally at least two independent subject-matter experts
Ethics framework
COPE and ICMJE guidance; iThenticate similarity screening

Editorial decisions are based on scope, scientific quality, methodological rigor, ethical compliance, reporting quality, and relevance to the journal. Board membership confers no advantage in review or acceptance. See the editorial policies and article processing charges.

Submitting to JHOR

The 63 articles this journal has published since 2014 were assessed by the editors listed above. If your work sits inside the scope, the author instructions set out the submission route and the manuscript requirements in full.

Menu